Anticancer Analysis of CD44 Targeted Cyclosporine Loaded Thiolated Chitosan Nanoformulations for Sustained Release in Triple-Negative Breast Cancer
International Journal of Nanomedicine · 2023
DOI: 10.2147/ijn.s424932 ↗Kurz gefasst
Zurückgezogene Publikation in der Zeitschrift International Journal of Nanomedicine, 2023. Verfasst von Maisa Siddiq Abduh. Beteiligte Einrichtung: Immune Responses in Different Diseases Research Group, Department of Medical Laboratory Sciences, Faculty of Applied Medical Sciences, King Abdulaziz…. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Chitosan, Nanoparticles. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Immune Responses in Different Diseases Research Group, Department of Medical Laboratory Sciences, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia.
- Center of Excellence in Genomic Medicine Research, King Abdulaziz University, Jeddah, Saudi Arabia.
ORCID-Profile: Maisa Siddiq Abduh
Zitieren
APA
Abduh, M. S. (2023). Anticancer Analysis of CD44 Targeted Cyclosporine Loaded Thiolated Chitosan Nanoformulations for Sustained Release in Triple-Negative Breast Cancer. International Journal of Nanomedicine. https://doi.org/10.2147/ijn.s424932
Vancouver
Abduh MS. Anticancer Analysis of CD44 Targeted Cyclosporine Loaded Thiolated Chitosan Nanoformulations for Sustained Release in Triple-Negative Breast Cancer. International Journal of Nanomedicine. 2023. doi:10.2147/ijn.s424932
BibTeX
@article{Abduh2023,
author = {Abduh, Maisa Siddiq},
title = {Anticancer Analysis of CD44 Targeted Cyclosporine Loaded Thiolated Chitosan Nanoformulations for Sustained Release in Triple-Negative Breast Cancer},
journal = {International Journal of Nanomedicine},
year = {2023},
doi = {10.2147/ijn.s424932}
}
EUVIMED